Topical Effectiveness of Different Concentrations of Nanosilver Solution on Leishmania Major Lesions in Mice (Balb/c)

Document Type : Original Article (s)

Authors

1 Associate Professor, Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran

2 Researcher, Department of Medical Entomology, Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

3 Department of Medical Entomology, National Institute of Health Research, Isfahan Health Research Station, Tehran University of Medical Sciences, Tehran, Iran

4 Researcher, Department of Microbiology, Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

5 General Practitioner, Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

6 Specialist in Infectious Disease, Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

7 National Institute of Health Research, Isfahan Health Research Station, Tehran University of Medical Sciences, Tehran, Iran

8 Department of Medical Parasitology, National Institute of Health Research, Isfahan Health Research Station, Tehran University of Medical Sciences, Tehran, Iran

Abstract

Background: Cutaneous leishmaniasis is an infection caused by protozoan genus leishmania the incidence rate of which has been estimated as 0.28 in every 1000 individuals in Iran. Although glucantime is commonly used to treat leishmaniasis, it has some side effects including increased liver enzymes and electrocardiogram changes. In addition, the drug is expensive, the injection is painful, and research shows that glucantime resistance of parasite is growing in different parts. Therefore, scientists are paying more attention to new drugs such as nanosilver solution. The present study tried to evaluate the in-vivo topical effects of different concentrations of nanosilver solution.Methods: Colloidal particles were used in this study. Female Balb/c rats aged 6-8 weeks were studied in groups of 10. Different concentrations [60, 80, 120, 130, and 2000 particles per million (ppm)] of nanosilver 4000 were prepared (Nano Alvand, Arad Co., Iran). Rats were subcutaneously injected at the base of the tail with 0.1 ml of solution containing the parasite. Clinical control of the infection trends was conducted weekly for 6 weeks by measuring lesion diameter at the base of the tail. Data was analyzed by paired t-test, analysis of variance (ANOVA), and Tukey test. The significance level was considered as P < 0.05.Findings: Mean lesion diameter before and after the treatment did not significantly differ between different groups (P > 0.05). Likewise, a significant difference in splenic parasite load was not observed between different treatment groups. Conclusion: Based on our results, different concentrations of nanosilver are ineffective in reducing mean sizes of lesions. However, nanosilver can be used in treating secondary infections in patients with cutaneous leishmaniasis.

Keywords

References

  1. John DT, Petri WA. Markell and Voge's Medical Parasitology. 9th ed. Philadelphia: WB. Saunders; 2006.
  2. Saebi A. Parasitic Disease In Iran, Protozoan Diseases. Tehran: Enghelabe Eslami Publications and Eduaction Organization; 2003.
  3. Hadighi R, Mohebali M, Boucher P, Hajjaran H, Khamesipour A, Ouellette M. Unresponsiveness to Glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites. PLoS Med 2006; 3(5): e162.
  4. Marquis N, Gourbal B, Rosen BP, Mukhopadhyay R, Ouellette M. Modulation in aquaglyceroporin AQP1 gene transcript levels in drug-resistant Leishmania. Mol Microbiol 2005; 57(6): 1690-9.
  5. Arevalo I, Ward B, Miller R, Meng TC, Najar E, Alvarez E, et al. Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. Clin Infect Dis 2001; 33(11): 1847-51.
  6. Lupton JR, Alster TS. Laser scar revision. Dermatol Clin 2002; 20(1): 55-65.
  7. al-Majali O, Routh HB, Abuloham O, Bhowmik KR, Muhsen M, Hebeheba H. A 2-year study of liquid nitrogen therapy in cutaneous leishmaniasis. Int J Dermatol 1997; 36(6): 460-2.
  8. Antibacterial Effects of Silver. [Online]; Available from: URL: http://en.wikipedia.org/wiki/silver/ antibacterial effects of silver.
  9. Nanotech Facts. [Online]; Available from: URL: http://www.nanosilver.com.my/nanotech.asp.
  10. Jose L Elechiguerra JL, Justin L Burt JL, Jose R Morones JR, Alejandra Camacho-Bragado A, Xiaoxia Gao X, et al. Interaction of silver nanoparticles with HIV-1. [Online] 2005 Mar 28; [cited 2005 Jun 29]; Available from: URL: http://www.jnanobiotechnology.com/content/3/1/6
  11. Hejazi HS, Tahani M. Study of Therapeutic Effect of Traditional Ointment on Cutaneous Leishameniasis in Animal Model [Thesis]. Isfahan: Isfahan University of Medical Sciences; 1999.
  12. Mohbali M, Yaghobi P, Hooshmand P, khamesi poor A. Paromomycin ointment made in Iran (Paramo - io) in the mouse model of cutaneous leishmaniasis caused by Leishmania major. Iranian Journal Of Dermatology 2003; 7(2): 88-94.
  13. Melby PC, Yang YZ, Cheng J, Zhao W. Regional differences in the cellular immune response to experimental cutaneous or visceral infection with Leishmania donovani. Infect Immun 1998; 66(1): 18-27.
  14. Ardehai SD. Leishmania Parasite and Leishmaniasis. Tehran: University Publishing Center; 1985.
  15. Gunawan C, Teoh WY, Marquis CP, Lifia J, Amal R. Reversible antimicrobial photoswitching in nanosilver. Small 2009; 5(3): 341-4.
  16. Mehrbod P, Motamed N, Tabatabaian M, Soleimani Estyar R, Amini E, Shahidi M, et al. Invitro antiviral effect of "Nanosilver" on influenza virus. DARU Journal of Pharmaceutical Sciences 2009; 17(2): 88-93.
  17. Weigel MM, Armijos RX, Avila A, Burgos X, Martinez LJ. In-vitro study of the antileishmanicidal activity of nanosilver. Proceedings of the 11th International Congress of Parasitology; 2006 Aug 6-11; Glasgow, Scotland.
  18. Mohebali M, Rezayat M.M, Gilani K, Sarkar S, Akhoundi B, Esmaeili J, et al. Nanosilver in the treatment of localized cutaneous leishmaniasis caused by Leishmania major (MRHO/IR/75/ER): an in vitro and in vivo study. DARU Journal of Pharmaceutical Sciences 2009; 17(4): 285-9.
Journal of Isfahan Medical School
Volume 29, Issue 158 - Serial Number 158
September and October 2011
Pages 1575-1582

Files

History

  • Receive Date: 02 March 2011
  • Revise Date: 02 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics